Pharma

Enhertu, Hutchmed, BeiGene-Novartis—Fierce Pharma Asia

Enhertu receives a landmark HER2-low nod. Hutchmed turns in positive data for two cancer drugs. Novartis and BeiGene's PD-1 meets liver cancer goal.
Angus Liu Aug 12, 2022 9:50am

COVID-19 tracker: Emergent, Pfizer, CDC, China, Shanghai

Aug 12, 2022 9:30am

Spectrum Science snaps up Aurora to boost Europe footprint

Aug 12, 2022 9:30am

ViiV sets up monkeypox fund to deliver $500,000 in the US

Aug 12, 2022 9:15am

Diabetes brand awareness in the doldrums

Aug 12, 2022 9:00am

Amgen is the latest drugmaker in Senate committee's tax probe

Aug 12, 2022 8:56am
Marketing News

Hanmi relaunches liver drug after boosting bioavailability

Jul 12, 2022 9:10am

Biora, with spin on Xeljanz nearing clinic, posts delivery data

Jul 11, 2022 12:45pm

Chiesi enlists support for nose-to-brain biologic delivery push

Jul 11, 2022 12:30pm

Novartis’ new rare disease drug Vijoice meant as 'blank canvas'

Aug 10, 2022 10:29am